Navigation Links
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
Date:7/11/2014

MISSISSAUGA, ON, July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that Health Canada approved APTIOMTM (eslicarbazepine acetate) for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy.  APTIOMTM is not indicated for use in patients under 18 years of age.

Epilepsy is one of the most common neurological disorders and according to Epilepsy Canada, it affects 0.6% of the population and each year approximately 15,500 people learn they have epilepsy.  Partial-onset seizures are the most prevalent seizure type, accounting for 60% of new epilepsy diagnoses1 and approximately one third of patients do not have adequate seizure control5.

The approval of APTIOMTM is based on three Phase 3 randomized, double-blind, placebo-controlled, safety and efficacy trials (Studies BIA-2093-301, BIA-2093-302 and BIA-2093-304), which included more than 1,400 people living with partial-onset seizures inadequately controlled by one to three concomitant AEDs (including carbamazepine, lamotrigine, valproic acid and levetiracetam). In these global studies,  treatment with APTIOMTM demonstrated statistically significant reductions in standardized seizure frequency versus placebo, and significantly more APTIOMTM treated patients experienced seizure frequency reduction of 50% or more from baseline (41% compared to 22% for placebo-treated patients).

The most frequently reported adverse reactions in patients taking APTIOMTM were dizziness, somnolence, headache, nausea, diplopia, vomiting, fatigue, ataxia, vision blurred, and vertigo.

"The approval of APTIOMTM is an important milestone not only for our company, but for thousands of Canadians living with, and affected by epile
'/>"/>

SOURCE Sunovion Pharmaceuticals Canada Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
2. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
3. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
4. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
5. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
6. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
7. Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
8. Avanir Pharmaceuticals to Participate in Two Conferences in December
9. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
10. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
11. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Over the last decade, the ... rising R&D budgets and increased acceptance of new filtration ... and biotechnology industries are also catalyzing the growth of ... is expected to grow at a strong CAGR during ... be worth $2,532.6 million by 2019. The market is ...
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
(Date:9/30/2014)... Sept. 30, 2014 CORD:USE Cord Blood Bank ... that it has entered into an Equity and Exclusive ... has licensed a series of patented technologies for the isolation ... clinical applications.  Tianhe is performing Phase I/II clinical trials ... Spain using Tianhe,s Stem Cell Educator Therapy ...
(Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
Breaking Biology Technology:Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... March 27 Zinsser Analytic and ThalesNano today announced ... in the territory of Germany, Switzerland and Austria."We are ... Zinsser is a leader in automation and a brand ... Ferenc Darvas, president and chairman of ThalesNano Inc. ...
... Calif., March 26 On March 18th, Frost ... diabetes research award. The award was given in recognition ... Test , which uses glycated albumin to ... body.(Photo: http://www.newscom.com/cgi-bin/prnh/20090326/LA89768 )Diabetes is one of the ...
... Microscopic World , ... Baltimore, MD (PRWEB) March 26, 2009 -- With ... the Maryland Science Center takes the same telescopic technology used to view ... is a 4,000 square foot exhibit featuring dozens of interactive components and ...
Cached Biology Technology:Zinsser Analytic and ThalesNano Collaborate on Distributing Products 2Frost & Sullivan Award Highlights Opportunity for 'Main Street' Biotech 2Cells Exhibition Opens at Maryland Science Center 2Cells Exhibition Opens at Maryland Science Center 3
(Date:9/30/2014)... The National Institutes of Health (NIH) awarded ... to develop an electrode array system that will ... works through unprecedented resolution and scale. , LLNL,s ... support President Obama,s BRAIN (Brain Research through ... effort to revolutionize our understanding of the human ...
(Date:9/30/2014)... can live in almost any aquatic environment on Earth, ... many species are pushed to the limit. The amount ... prove critical for how different species cope in the ... University of Gothenburg, published in the scientific journal ... change continues apace thanks to increasing levels of greenhouse ...
(Date:9/30/2014)... know what goes wrong with your muscles because of age, ... "normal" actually is. That,s where a new research report published ... Journal comes in. In the report, a team ... that can help scientists "see" which genes are active in ... never-before-detected gene activity and that men have approximately 400 more ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2
... OAK RIDGE, Tenn., Dec. 16, 2013 By controlling ... at the Department of Energy,s Oak Ridge National Laboratory ... solar cells, computer monitors, TV screens, eye glasses and ... structures and being able to precisely control the diameter ...
... Every year the approach of flu season sets off a ... many different strains of flu and they vary from year ... guess and tell manufacturers which variants of the flu they ... flu-related illnesses can kill 3,000 to 49,000 Americans annually, according ...
... a nucleic acid involved in protein synthesis, is widely ... expression in different organisms. The types and quantities of ... expressed, providing insight on the genes responsible for particular ... and quantitative PCR, are available for studying gene expression. ...
Cached Biology News:ORNL devises recipe to fine-tune diameter of silica rods 2Stanford researchers take a step toward developing a 'universal' flu vaccine 2Stanford researchers take a step toward developing a 'universal' flu vaccine 3Stanford researchers take a step toward developing a 'universal' flu vaccine 4A universal RNA extraction protocol for land plants 2A universal RNA extraction protocol for land plants 3
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Immunofixation Gel Kit, requires IF100 Reactivity: Human Applications: Immunofixation ...
Biology Products: